(Q35620878)

English

Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer

scientific article published on December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1

object named as

Sam S Chang

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

6 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

29-35

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Changes in body composition during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Lifetime risk of hip fractures is underestimated

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Do men and women fracture bones at similar bone densities?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Androgens: basic biology and clinical implication

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Aromatization of androgens is important for skeletal maintenance of aged male rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Long-term effects of androgen deprivation therapy in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Background to and management of treatment-related bone loss in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Management of treatment-related osteoporosis in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Transdermal estradiol therapy for advanced prostate cancer--forward to the past?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.10.006

7 January 2021

Identifiers

10.1016/J.UROLOGY.2003.10.006

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35620878&oldid=2049258585"